Zhongzhu Medical Holdings Co Ltd - Asset Resilience Ratio
Zhongzhu Medical Holdings Co Ltd (600568) has an Asset Resilience Ratio of 2.95% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 600568 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2023)
This chart shows how Zhongzhu Medical Holdings Co Ltd's Asset Resilience Ratio has changed over time. See 600568 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Zhongzhu Medical Holdings Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Zhongzhu Medical Holdings Co Ltd (600568) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥80.00 Million | 2.95% |
| Total Liquid Assets | CN¥80.00 Million | 2.95% |
Asset Resilience Insights
- Limited Liquidity: Zhongzhu Medical Holdings Co Ltd maintains only 2.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhongzhu Medical Holdings Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhongzhu Medical Holdings Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Zhongzhu Medical Holdings Co Ltd (2001–2023)
The table below shows the annual Asset Resilience Ratio data for Zhongzhu Medical Holdings Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 7.62% | CN¥230.00 Million ≈ $33.66 Million |
CN¥3.02 Billion ≈ $441.75 Million |
+6.68pp |
| 2022-12-31 | 0.94% | CN¥35.00 Million ≈ $5.12 Million |
CN¥3.71 Billion ≈ $543.28 Million |
-1.66pp |
| 2021-12-31 | 2.61% | CN¥116.24 Million ≈ $17.01 Million |
CN¥4.46 Billion ≈ $652.33 Million |
+2.52pp |
| 2018-12-31 | 0.09% | CN¥5.00 Million ≈ $731.66K |
CN¥5.62 Billion ≈ $822.28 Million |
-1.77pp |
| 2017-12-31 | 1.86% | CN¥135.38 Million ≈ $19.81 Million |
CN¥7.27 Billion ≈ $1.06 Billion |
-0.94pp |
| 2016-12-31 | 2.80% | CN¥200.00 Million ≈ $29.27 Million |
CN¥7.14 Billion ≈ $1.04 Billion |
+1.64pp |
| 2015-12-31 | 1.16% | CN¥50.00 Million ≈ $7.32 Million |
CN¥4.29 Billion ≈ $628.05 Million |
+1.15pp |
| 2013-12-31 | 0.02% | CN¥490.38K ≈ $71.76K |
CN¥2.64 Billion ≈ $386.45 Million |
-0.02pp |
| 2012-12-31 | 0.04% | CN¥961.54K ≈ $140.70K |
CN¥2.25 Billion ≈ $329.78 Million |
+0.02pp |
| 2011-12-31 | 0.02% | CN¥458.93K ≈ $67.16K |
CN¥2.10 Billion ≈ $306.67 Million |
-0.03pp |
| 2010-12-31 | 0.05% | CN¥998.00K ≈ $146.04K |
CN¥2.12 Billion ≈ $310.88 Million |
+0.04pp |
| 2005-12-31 | 0.01% | CN¥100.12K ≈ $14.65K |
CN¥1.38 Billion ≈ $202.35 Million |
-0.03pp |
| 2004-12-31 | 0.04% | CN¥300.00K ≈ $43.90K |
CN¥771.64 Million ≈ $112.91 Million |
-0.01pp |
| 2003-12-31 | 0.05% | CN¥300.00K ≈ $43.90K |
CN¥569.42 Million ≈ $83.32 Million |
+0.01pp |
| 2002-12-31 | 0.04% | CN¥200.00K ≈ $29.27K |
CN¥478.20 Million ≈ $69.98 Million |
-43.88pp |
| 2001-12-31 | 43.92% | CN¥202.18 Million ≈ $29.58 Million |
CN¥460.31 Million ≈ $67.36 Million |
-- |
About Zhongzhu Medical Holdings Co Ltd
Zhongzhu Healthcare Holding Co.,Ltd engages in the research and development, production, and sale of drugs in China. The company offers ophthalmology drugs, including Pearl eye drops, Sodium Cromolyn eye drops, Acyclovir eye drops, Hydroxybenzone Hydrochloride eye drops, Acyclovir dispersible tablets, and Gatifloxacin tablets; and products related to tumor treatment. It is also involved in produc… Read more